LFG
RAPP

Larson Financial Group’s Rapport Therapeutics RAPP Stock Holding History

Larson Financial Group’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.19K Buy
102
+19
+23% +$534 ﹤0.01% 2798
2025
Q4 		$2.52K Buy
+83
New +$2.3K ﹤0.01% 2713

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Larson Financial Group's RAPP Position: Q1 2026 in Review

Larson Financial Group increased its Rapport Therapeutics (RAPP) stake by 23% in Q1 2026, buying an estimated $534 and bringing the position to 102 shares worth $3.19K. The position accounts for ﹤0.01% of the portfolio, ranked #2798.

Larson Financial Group first reported a position in RAPP in Q4 2025 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Larson Financial Group held 102 shares of Rapport Therapeutics worth $3.19K as of Q1 2026.
  • Larson Financial Group bought 19 Rapport Therapeutics shares in Q1 2026, an estimated $534.
  • Rapport Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2798 holding.
  • Larson Financial Group first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.